NasdaqCM - Nasdaq Real Time Price USD

Quoin Pharmaceuticals, Ltd. (QNRX)

7.99
+0.29
+(3.77%)
At close: 4:00:00 PM EDT
8.00
+0.01
+(0.13%)
After hours: 4:09:59 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for QNRX

Recent News: QNRX

View More
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
GlobeNewswire 5 days ago
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results
GlobeNewswire 6 days ago
Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025
GlobeNewswire 13 days ago
Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
GlobeNewswire 19 days ago
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
GlobeNewswire last month
Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient
GlobeNewswire last month
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
GlobeNewswire last month

QNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26
Zacks Small Cap Research 2 months ago
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
GlobeNewswire 2 months ago
Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025

Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025
GlobeNewswire 2 months ago
QNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the Disease

QNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the Disease
Zacks Small Cap Research 2 months ago
View More

Related Tickers

CNSP CNS Pharmaceuticals, Inc.
1.2900
+0.78%
 
HCWB HCW Biologics Inc.
8.57
-4.25%
 
KLTO Klotho Neurosciences, Inc.
0.2310
+2.85%
 
XLO Xilio Therapeutics, Inc.
0.8800
+2.40%
 
ABP Abpro Corporation
0.2720
+18.26%
 
KTTA Pasithea Therapeutics Corp.
0.9419
-1.47%
 
NCNA NuCana plc
0.0482
+10.05%
 
CTMX CytomX Therapeutics, Inc.
2.1300
+4.93%
 
INZY Inozyme Pharma, Inc.
3.9900
+1.01%
 
AFMD Affimed N.V.
0.1815
-34.95%